ライフサイエンスコーパス: recurrence risk

1 serve as imaging biomarkers of breast cancer recurrence risk.

2 s that beta-blockers attenuate breast cancer recurrence risk.

3 alcium stone, increased fluid intake reduced recurrence risk.

4 ransplantation model for posttransplantation recurrence risk.

5 ute to resection completeness and reduce the recurrence risk.

6 ropriate for treating PSP patients with high recurrence risk.

7 of postpartum AD, duration of treatment, and recurrence risk.

8 clinical prediction rule that stratifies VTE recurrence risk.

9 ss an individual patient's tumor biology and recurrence risk.

10 of comorbidities were associated with higher recurrence risk.

11 -fetoprotein (AFP) have been associated with recurrence risk.

12 aracteristics and ERP, and estimated sibling recurrence risk.

13 rs in identifying patients with an increased recurrence risk.

14 n have emerged as the primary determinant of recurrence risk.

15 etastases in lymph nodes and better estimate recurrence risk.

16 is unlikely to cause substantially increased recurrence risk.

17 ion on mechanism of origin, inheritance, and recurrence risk.

18 mutation site may be important in assessing recurrence risk.

19 ogic, and treatment features known to affect recurrence risk.

20 involvement in breast cancer is a marker of recurrence risk.

21 ncluding rare individual pedigrees with high recurrence risk.

22 sus dizygotic (5%) twins as well as familial recurrence risk.

23 ening corrected QT interval and reducing TdP recurrence risk.

24 marginally associated with a decline in the recurrence risk.

25 6% not accepting a less than 5% reduction in recurrence risk.

26 m-effects model and used to calculate 5-year recurrence risk.

27 treatment, geography, Child-Pugh status, and recurrence risk.

28 f CHD with chromosome abnormalities and high recurrence risk.

29 rombotic burden can identify subjects at low recurrence risk.

30 ese predictors may be useful for stratifying recurrence risk.

31 ual SNPs were at most mildly associated with recurrence risk.

32 able couples to be counseled as to their low recurrence risk.

33 d parental mosaicism as central variables in recurrence risk.

34 h the procedure has not been shown to reduce recurrence risk.

35 dneys from living donors (LD) have increased recurrence risk.

36 f mosaic trisomy and UPD and (iii) potential recurrence risks.

37 nd 24.6% in validation set) without additive recurrence risks.

38 after ASD index cases were used to calculate recurrence risks.

39 8%) and that BCS has a slightly higher local recurrence risk (63%); most accurately identified the ma

40 dentified the magnitude of ipsilateral local recurrence risk (91%).

41 xonidine treatment was associated with lower recurrence risk after adjustment for age, body mass inde

42 dated Vienna Prediction Model for estimating recurrence risk after an unprovoked venous thromboemboli

43 Independent predictors of survival and recurrence risk after curative-intent surgery for ACC we

44 ociated with ductal carcinoma in situ (DCIS) recurrence risk after definitive treatment.

45 rnational bladder cancer nomogram predicting recurrence risk after radical cystectomy for bladder can

46 comes nomogram to predict the 5-year disease recurrence risk after radical cystectomy.

47 exposure to mood stabilizers versus the high recurrence risks after discontinuing lithium.

48 of non-RCC death exceeded that of abdominal recurrence risk already at 30 days after surgery, regard

49 Recurrence risk also increased with increasing age, prev

50 having an affected child, and determined the recurrence risks among the siblings and offspring of aff

51 Accurate assessments of recurrence risk and absolute treatment benefit are neede

52 more accurate information to assess disease recurrence risk and BC-related death.

53 develop multigene algorithms for estimating recurrence risk and benefit from FU/LV.

54 uantitative gene expression assays to assess recurrence risk and benefits from chemotherapy in patien

55 ing the underlying parameters that influence recurrence risk and could be useful for analyzing risk i

56 A key outcome is clarification of recurrence risk and facilitation of reproductive choices

57 erage risk, they will not contribute much to recurrence risk and heritability unless they persist on

58 for preventing gastric cancer will depend on recurrence risk and individual and community factors.

59 genes showed a significant trend for reduced recurrence risk and longer recurrence-free survival as t

60 mical markers to stratify patients regarding recurrence risk and may inform treatment decisions.

61 nderlying aetiology, theranostic strategies, recurrence risk and path to recovery are populated by a

62 em to be necessary and sufficient to explain recurrence risk and population incidence.

63 tatistically significant association between recurrence risk and receptor status.

64 linical cohort study, the authors determined recurrence risk and survival-analysis-based time to recu

65 r understanding of cancer origin, evolution, recurrence-risk and treatment diagnostics.

66 n insight into prognosis, inform families of recurrence risk, and facilitate prenatal diagnoses.

67 h CD68 score and Ki-67 index correlated with recurrence risk, and Ki-67 index inversely correlated wi

68 Ascribing causality, determination of recurrence risk, and prognostication for rare or unique

69 of genomic predictors of ER pathway status, recurrence risk, and sensitivity to chemotherapeutics wa

70 ns of nipple viability, flap necrosis, local recurrence risk, and the technical challenge of this pro

71 agnosis, to counsel family members for their recurrence risk, and to classify these rare disorders mo

72 alysis of the symptom loadings, comorbidity, recurrence risks, and within-family correlations indicat

73 ans and mice, CHD has a low absolute sibling recurrence risk ( approximately 2.7%), suggesting a cons

74 idering Mendelian diseases in which familial recurrence risks are high, and mutant alleles are both n

75 Thus, although early mortality and stroke recurrence risks are higher among non-lacunar than lacun

76 The familial recurrence risks are low when the child has de novo unip

77 the context of common traits, where familial recurrence risks are modest, and for the most part the r

78 mptom reduction for even a small increase in recurrence risk, are at substantially increased risk of

79 DCE MR imaging features were predictive of recurrence risk as determined by the surrogate assay, wi

80 esults demonstrate no time trend in the ASDs recurrence risk as seen in the ASDs prevalence.

81 tor-positive, HER2-negative disease and high recurrence risk, as defined by clinicopathologic charact

82 s in breast cancer diagnosis, prognosis, and recurrence risk assessment.

83 No variation in the recurrence risk associated with change of municipality o

84 of non-RCC death exceeded that of abdominal recurrence risk at 6 months in patients age 80 years and

85 al study cannot specifically examine adenoma recurrence risk at intervals suggested for patients with

86 Recurrence risks at 3 years were 12%, 18%, and 22% for p

87 ive, face-based ABM reduced both measures of recurrence risk (Beck Depression Inventory and cortisol

88 The difference in the recurrence risk between full- and half-siblings supports

89 .1, all P < 0.001) and accurately stratified recurrence risk beyond MC, ranging from 19% (CRS 0) to 6

90 Melanoma recurrence risks beyond 5 years were derived from intern

91 , active dual-chamber pacing reduces syncope recurrence risk by 75% (95% confidence interval, 44-88).

92 istic, 0.82; 95% CI, 0.77-0.86) and superior recurrence risk classification compared with explant Mil

93 MAs had higher stroke recurrence risk compared with non-Hispanic white patient

94 0.84]) each further reduced composite stone recurrence risk compared with placebo or control, althou

95 drug-treated patients, dual-site RA reduced recurrence risk compared with SP (HR = 0.638, p = 0.011)

96 ristic phenotype is important due to the low recurrence risk compared with the other (recessive) cere

97 ) by exome sequencing, with implications for recurrence risk counseling.

98 Stroke recurrence risk decreased over time from sentinel stroke

99 Patients with the highest initial recurrence risk demonstrated the greatest increase in co

100 Our population-based recurrence risk estimate is lower than the recently repo

101 The recurrence risk estimates provide an important clinical

102 These findings have implications for recurrence risk estimation and genetic counseling.

103 according to whether or not the 5-year local recurrence risk exceeded 10% (<10%, 17,000 women; >10%,

104 Recurrence risk factors of greatest significance were ap

105 , there are no definitive data regarding its recurrence risk factors.

106 lysis identified 3 statistically significant recurrence risk factors: advanced age, largest basal dia

107 The overall relative recurrence risk for ASDs was 6.9 (95% CI, 6.1-7.8), and

108 first population-based study to examine the recurrence risk for autism spectrum disorders (ASDs), in

109 Recurrence risk for CHD in offspring was 4.8%, with no s

110 sm indicates that there may be a significant recurrence risk for DC/XLIS in families at risk, even wh

111 The recurrence risk for depression or panic was much shorter

112 A continuous, composite measure of recurrence risk for each patient was determined from a C

113 complications for their patients and predict recurrence risk for families of children with congenital

114 ds, and the first study to consider the ASDs recurrence risk for full- and half-siblings.

115 isk for developing disease and calculate the recurrence risk for future offspring.

116 The sibling recurrence risk for HLHS was 8%, and for CVM was 22%.

117 Few reliable data exist concerning the recurrence risk for individual trisomies or the risk for

118 The recurrence risk for JIA was significantly elevated among

119 al half siblings (2.3%) was half the overall recurrence risk for maternal half siblings but was simil

120 The recurrence risk for paternal half siblings (2.3%) was ha

121 The mean sibling recurrence risk for TS/CT across all birth years was 9.8

122 The authors sought to determine the illness recurrence risk for women with bipolar disorder who disc

123 Recurrence risks for JIA were computed for relatives of

124 iting the range of genetic determination and recurrence risks for two-, three-, and four-locus purely

125 Seven recurrence-risk genes, six FU/LV-benefit genes, and five

126 substantive implications for calculation of recurrence risk, genetic counseling, and potential treat

127 % for predefined low, intermediate, and high recurrence risk groups, respectively.

128 The genotype-specific recurrence risk (GSR) is the genotype-specific risk to r

129 The observed pattern of familial recurrence risk has long suggested that multiple variant

130 ant chemotherapy was associated with overall recurrence risk (hazard ratio [HR] = 0.56), while histor

131 -6 genotype was associated with an increased recurrence risk (hazard ratio [HR], 4.60; 95% CI, 1.24 t

132 Patients were stratified by recurrence risk, histology, Eastern Cooperative Oncology

133 le was associated with significantly reduced recurrence risk (HR = 0.25; 95% CI, 0.10 to 0.64) and im

134 PPARG genotype was associated with a reduced recurrence risk (HR, 0.41; 95% CI, 0.20 to 0.86) among u

135 Sibling recurrence risk in autism has been estimated to be appro

136 ovides information in assessing the clinical recurrence risk in bladder cancer and that the specific

137 90th percentile also had greater categorical recurrence risk in both TEDS and CATSS.

138 By identifying VTE recurrence risk in cancer patients with VTE, we may be a

139 se of single affected parents shows that the recurrence risk in children is determined by genetic fac

140 multigene signature to improve prediction of recurrence risk in clear cell renal cell carcinoma.

141 clinically important question of predicting recurrence risk in colorectal cancer patients, we demons

142 tative distributions in nature, estimates of recurrence risk in families have never previously consid

143 tients and may be helpful in determining the recurrence risk in families.

144 As recurrence risk in hormone receptor-positive breast canc

145 e of genetics in ASDs, while the significant recurrence risk in maternal half-siblings may support th

146 quency of conjugal MS and have estimated the recurrence risk in offspring of such matings.

147 of these findings, we hypothesized a higher recurrence risk in older than in younger patients when t

148 ance (MR) imaging features and breast cancer recurrence risk in patients with estrogen receptor-posit

149 ted in a prospective study for assessment of recurrence risk in patients with stage II colon cancer a

150 was able to reduce intermediate measures of recurrence risk in previously depressed patients.

151 robust demonstration of an fMRI signature of recurrence risk in remitted MDD.

152 tic architectures underlying the low sibling recurrence risk in S-CHD and NS-CHD.

153 The recurrence risk in second-born children was higher (11.5

154 The 12-gene Recurrence Score predicts recurrence risk in stage II and stage III colon cancer a

155 a genomic signature developed both to assess recurrence risk in stage II patients and to assist in tr

156 We have compared recurrence risks in half-siblings with respect to their

157 factor scores to comorbidity in probands and recurrence risks in relatives were examined.

158 Calculation of recurrence risks in siblings largely confirmed the herit

159 increase in diameter, the estimated rate of recurrence risk increased by 198%.

160 The 4-month recurrence risk increased by approximately 5% (absolute)

161 ; however, an optimistic under-estimation of recurrence risk is a common problem associated with thes

162 In simple D-TGA: 1) familial recurrence risk is low; 2) children diagnosed pre-natall

163 Recurrence risk is mostly associated with presence of re

164 cies may frequently be cured with resection, recurrence risk is significant.

165 E) recurrence, but further stratification of recurrence risk is uncertain.

166 t, identification of patients at low risk of recurrence risk is very difficult (that is, such people

167 bar intracerebral haemorrhage (with its high recurrence risk) is now well recognised, a number of man

168 garding the association between genotype and recurrence risk, is premature.

169 Age and gender-adjusted OR(s) and sibling recurrence risk (lambda(s)), with different thresholds d

170 e weighted MLS was 2.06 on 20q (chi = 57 cM, recurrence risk,lambda(s) = 1.25, P = 0.009).

171 nature predicted particularly well for early recurrence risk (<2 years), especially when combined wit

172 solute gains from radiotherapy; 5-year local recurrence risks (mainly at these sites) 6% versus 23% (

173 to the conserved breast), with 5-year local recurrence risks (mainly in the conserved breast, as mos

174 Degrees of gonosomal mosaicism mean that recurrence risks may well be <50% in the index case when

175 About three-quarters of the eventual local recurrence risk occurred during the first 5 years.

176 staining did not confer an increased risk of recurrence (risk of recurrence, 0.86, P = 0.78), whereas

177 me 17p appeared to be highly correlated with recurrence (risk of recurrence, 3.7, P = 0.003).

178 .35; I(2) = 73%) leading to a summary 5-year recurrence risk of 0.95% (95% CI, .35%-1.69%).

179 -up UBT (n=1091), 125 tested UBT positive, a recurrence risk of 11.5% (95% CI, 9.6%-13.5%).

180 gy of TOF is multifactorial, with a familial recurrence risk of 3%.

181 nt heart defects in 16 liveborn offspring--a recurrence risk of 4.1%.

182 ct of epigenetic inheritance on the risk and recurrence risk of a complex disease.

183 ermine the true rate of familial ALS and the recurrence risk of ALS in family members, and to identif

184 identifiable provocative risk factors have a recurrence risk of approximately 25% at 4 years with the

185 FA supplementation reduced the recurrence risk of Cd exencephaly by as much as 55%.

186 The authors investigated the recurrence risk of congenital anomalies as a function of

187 ne or more successful pregnancies with a low-recurrence risk of congenital heart disease.

188 cs, with 98% both incorrectly estimating the recurrence risk of deafness and misunderstanding the con

189 This study defines the incidence and recurrence risk of Hodgkin disease (HD) and non-Hodgkin

190 The familial recurrence risk of lymphatic filariasis (LF) is unknown.

191 The recurrence risk of postpartum AD for women with a PPD ho

192 The recurrence risk of postpartum AD was markedly higher amo

193 Prediction of biochemical recurrence risk of prostate cancer following radical pro

194 of 2 functional MDM2 promoter variants with recurrence risk of SCCOP.

195 ed low and high RS groups had average 5-year recurrence risks of 13% (95% CI, 10% to 16%) and 21% (95

196 findings have important consequences for the recurrence risks of disorders caused by de novo mutation

197 t outcome predictor strongly associated with recurrence, risk of death, and shorter survival.

198 uled out linkage at 14q21-23 (lambda(s) [sib recurrence risk or genotypic risk ratio] = 1.8).

199 us at enrollment was associated with a lower recurrence risk (OR = 0.67, 95% CI 0.45, 0.99, for the m

200 ve surgical margin does not affect survival, recurrence risk, or site of recurrence.

201 liability, approximate heritability, sibling recurrence risk, overall genetic variance using a logari

202 Recurrence Score predicted recurrence risk (P = .001) after adjustment for stage, m

203 Recurrence risk peaked near 14 months for both treatment

204 Recurrence risk period was between approximately 45 and

205 and might ultimately lead to improvements in recurrence risk prediction, treatment, and prognosis.

206 eceiver operating curve) of established GIST recurrence risk prognostic scoring systems.

207 RETREAT was able to stratify 5-year post-LT recurrence risk ranging from less than 3% with a score o

208 associated with an increased risk of disease recurrence (risk rate, 3.12; P =.02) and decreased risk

209 therapy significantly reduced risk of stroke recurrence (risk ratio, 0.69; 95% confidence interval, 0

210 MAs had higher risk for stroke recurrence (risk ratio, 1.57; 95% confidence interval, 1

211 The estimated sibling recurrence risk ratio (lambdas ) for fibromyalgia was 13

212 The estimated sibling recurrence risk ratio (lambdas ) observed in this study

213 The recurrence risk ratio (RRR) is calculated to assess and

214 da(R)/lambda(jR), where lambda(R) is Risch's recurrence risk ratio and lambda(jR) is the contribution

215 The sibling recurrence risk ratio for the disease is 63 and heritabi

216 als with ERP had an ERP prevalence of 11.6% (recurrence risk ratio of 1.89).

217 The recurrence risk ratio of BAV in HLHS families (8.05) was

218 The lambdas and the parent-offspring recurrence risk ratio of RRD were 2.1 (95% CI, 1.3-3.2)

219 ed prevalence rates, we calculated a sibling recurrence risk ratio of up to 18.9.

220 netic contribution of >10% to the AS sibling recurrence risk ratio) within this area contributing to

221 ex diseases with large values of the sibling recurrence risk ratio, sequencing unselected affected in

222 es with small values for the overall sibling recurrence risk ratio, such as Alzheimer's disease and m

223 We introduce the idea of a restricted sib recurrence-risk ratio (lambda*S) estimated by restrictio

224 The recurrence-risk ratio of disease in siblings, lambdaS, i

225 asure of familial aggregation is the sibling recurrence-risk ratio, which is defined as the ratio of

226 Sibling-sibling recurrence risk ratios (lambdas) and parent-offspring re

227 Frequencies, recurrence risk ratios (RRRs), heritability, and twin co

228 Subsets linkage analyses and recurrence risk ratios in a combined cohort provide evid

229 e risk ratios (lambdas) and parent-offspring recurrence risk ratios were calculated.

230 t interbirth interval was observed, with the recurrence risk reaching 14.4% for an interbirth interva

231 because data suggest increased locoregional recurrence risks (relative to luminal subtypes) with bre

232 opic pleurodesis procedure for PSP with high recurrence risk remains controversial.

233 can benefit families with information about recurrence risk, resolve concerns about etiology, provid

234 HRT did not seem to affect breast cancer recurrence risk (RR = 0.64, 95% confidence interval [CI]

235 The prevalence of TS/CT and OCD and relative recurrence risk (RRR) for TS/CT or OCD among individuals

236 The relative recurrence risk (RRR) measures familial aggregation of d

237 omy and open nephroureterectomy, investigate recurrence risks specific to laparoscopic nephroureterec

238 enetic etiology is indicated by an increased recurrence risk, sporadic occurrence suggests that CHD g

239 ts that mutations in parental blood increase recurrence risk substantially more than parental mutatio

240 sms had significantly worse DFS and a higher recurrence risk than patients with fewer combined risk g

241 Purged autotransplantation had a 26% lower recurrence risk than unpurged autotransplantation.

242 ved little (<10%) difference in 5-year local recurrence risk there was little difference in 15-year b

243 As a consequence, the recurrence risk to close relatives is reduced.

244 olute treatment effect across a continuum of recurrence risk to individualize endocrine therapy decis

245 tionship R for the true model and KRI is the recurrence risk to relatives for a multiplicative model

246 nteraction ratio, CR=KR/KRI, where KR is the recurrence risk to relatives with relationship R for the

247 sex bias in AS, and there are differences in recurrence risk to the offspring of affected mothers and

248 Reproductive fitness of adults with TOF and recurrence risks to offspring are of increasing interest

249 al with secondary data on long-term melanoma recurrence risks to project the cost-effectiveness of ad

250 Additionally, recurrence risks to siblings were analyzed.

251 y regimens should take into account baseline recurrence risk, toxicities, likelihood of benefit, and

252 Thus, we aimed to predict ccRCC recurrence risk using lncRNA expression.

253 s 3 to 6 months, and acceptable reduction in recurrence risk was 0.5% to 1.0%.

254 The overall sibling recurrence risk was 10.1%, compared with a prevalence of

255 icial effect of ER- or PR-positive tumors on recurrence risk was absent.

256 Recurrence risk was greater after rapid than after gradu

257 Recurrence risk was higher in patients with higher prote

258 Regarding the 31-SNP GRS, recurrence risk was highest in patients with >/=31 and l

259 Recurrence risk was independently and significantly high

260 on, a validated model of posttransplantation recurrence risk was produced with a concordance statisti

261 However, recurrence risk was significantly decreased (adjusted ha

262 The recurrence risk was significantly higher for siblings wh

263 Among ever-users of HRT, recurrence risk was two-fold lower for estrogen receptor

264 versus continued mood stabilizer treatment, recurrence risk was twofold greater, median time to firs

265 The relative recurrence risks were 2.4 (95% CI, 1.4-4.1) for maternal

266 al (>10%) differences, however, 5-year local recurrence risks were 7% active versus 26% control (abso

267 nd combined polymorphisms, the above similar recurrence risks were particularly higher among patients

268 nosis, and model predictions of age-specific recurrence risks were tested against outcome data from S

269 does not define a subgroup that is at higher recurrence risk when compared with patients with RT-PCR-

270 These results validate the recurrence risks which have previously been derived from

271 d fosters genetic counseling with respect to recurrence risks while assuring reproductive choices.

272 urgery, trauma, pregnancy) have a low annual recurrence risk, while patients without identifiable pro

273 We observed an increased recurrence risk with genetic variations in AKT1 and AKT2

274 The increased recurrence risk with living donor liver transplantation